Lastly, using the ROC Plotter tool, we found that NSMCE2 high expression levels do not correlate with patients’ response to therapy for ovarian cancer, colorectal cancer, and glioblastoma [47, 48] (data not shown), thus, confirming that high levels of NSMCE2 gene expression are specifically associated with breast cancer patients’ poor response to chemotherapy. This evidence concerns the gene NSMCE2 and breast cancer.